Apr 1, 2026 7:45 am EDT TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Mar 23, 2026 7:45 am EDT Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
Feb 27, 2026 7:30 am EST TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Feb 17, 2026 7:45 am EST TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
Feb 12, 2026 7:45 am EST TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 2, 2026 7:45 am EST TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
Dec 15, 2025 7:50 am EST TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone